Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice
2020 ◽
Vol 44
(4)
◽
pp. 394-402
◽
2016 ◽
Vol 292
(4)
◽
pp. 1267-1287
◽